{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:14:00Z","timestamp":1780690440744,"version":"3.54.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nuclear protein in testis (NUT) carcinoma is an extremely rare and aggressive malignancy characterized by NUTM1 gene rearrangement. It frequently develops in the lungs or the head and neck region as a poorly differentiated squamous cell carcinoma. The prognosis is generally poor and particularly dismal in cases with a pulmonary origin. Given the lack of an established standard treatment and the rapid disease progression, recently, immune checkpoint inhibitors (ICIs) have attracted attention, particularly in combination with platinum-based chemotherapy. We report a case series of four patients with pulmonary NUT carcinoma who received ICI-containing regimens as first-line therapy. Three patients received ICIs in combination with platinum-based chemotherapy and showed transient tumor shrinkage, although all ultimately experienced disease progression and died. One patient received ICI monotherapy owing to poor performance status and showed no clinical response. The median progression-free and overall survival were 53 and 108\u00a0days, respectively. Given the limited treatment options for NUT carcinoma, a combination of ICIs with platinum-based chemotherapy may represent a potential first-line treatment option. However, their efficacy remains limited.<\/jats:p>","DOI":"10.1093\/jjco\/hyag025","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:07:50Z","timestamp":1769515670000},"page":"774-779","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitors in nuclear protein in testis carcinoma treatment: evidence of limited clinical benefits from a case series"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4248-8601","authenticated-orcid":false,"given":"Tomoaki","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4896-5824","authenticated-orcid":false,"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]},{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tateishi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-4184","authenticated-orcid":false,"given":"Yuki","family":"Shinno","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]},{"name":"Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-1526","authenticated-orcid":false,"given":"Tomonori","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-801X","authenticated-orcid":false,"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]},{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-559X","authenticated-orcid":false,"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7437-5054","authenticated-orcid":false,"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026060515390390900_ref1","first-page":"304","article-title":"BRD4-NUT fusion oncogene: A novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"2026060515390390900_ref2","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1158\/0008-5472.CAN-23-2545","article-title":"The BRD4\u2013NUT fusion alone drives malignant transformation of NUT carcinoma","volume":"83","author":"Durall","year":"2023","journal-title":"Cancer Res"},{"key":"2026060515390390900_ref3","doi-asserted-by":"publisher","first-page":"pkz094","DOI":"10.1093\/jncics\/pkz094","article-title":"An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2026060515390390900_ref4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jtho.2023.12.022","article-title":"Initial chemotherapy for locally advanced and metastatic NUT carcinoma","volume":"19","author":"Luo","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026060515390390900_ref5","doi-asserted-by":"crossref","first-page":"107496","DOI":"10.1016\/j.lungcan.2024.107496","article-title":"Clinical management of NUT carcinoma (NC) in Germany: analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients","volume":"189","author":"Kloker","year":"2024","journal-title":"Lung Cancer"},{"key":"2026060515390390900_ref6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/jjco\/hyac033","article-title":"Nuclear protein of the testis midline carcinoma of the thorax","volume":"52","author":"Saiki","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2026060515390390900_ref7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13023-020-01449-x","article-title":"Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma","volume":"15","author":"Xie","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026060515390390900_ref8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41571-025-00986-3","article-title":"Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck","volume":"22","author":"Luo","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026060515390390900_ref9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","article-title":"Clinical response of carcinomas harboring the BRD4\u2013NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628","volume":"6","author":"Stathis","year":"2016","journal-title":"Cancer Discov"},{"key":"2026060515390390900_ref10","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.annonc.2025.06.004","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"2026060515390390900_ref11","doi-asserted-by":"publisher","first-page":"e2400334","DOI":"10.1200\/PO.24.00334","article-title":"Multiomic characterization and molecular profiling of nuclear protein in testis carcinoma","volume":"8","author":"Kroening","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026060515390390900_ref12","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-25-1071","article-title":"Molecular characterization of NUT carcinoma: a report from the NUT carcinoma registry","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026060515390390900_ref13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"2026060515390390900_ref14","doi-asserted-by":"crossref","first-page":"102179","DOI":"10.1016\/j.ctrv.2021.102179","article-title":"Immunotherapy in non-small cell lung cancer harbouring driver mutations","volume":"96","author":"Addeo","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2026060515390390900_ref15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fonc.2022.914031","article-title":"NUT carcinoma\u2014an underdiagnosed malignancy","volume":"12","author":"Lauer","year":"2022","journal-title":"Front Oncol"},{"key":"2026060515390390900_ref16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/s41388-020-01625-0","article-title":"Supercharging BRD4 with NUT in carcinoma","volume":"40","author":"Eagen","year":"2021","journal-title":"Oncogene"},{"key":"2026060515390390900_ref17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.36401\/JIPO-23-19","article-title":"Sustained clinical response to immunotherapy followed by BET inhibitor in a patient with unresectable sinonasal NUT carcinoma","volume":"7","author":"Herbison","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"2026060515390390900_ref18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2021.01.018","article-title":"Bromodomain and extra-terminal inhibitors\u2014a consensus prioritisation after the paediatric strategy forum for medicinal product development of epigenetic modifiers in children\u2014ACCELERATE","volume":"146","author":"Pearson","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/774\/66852242\/hyag025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/774\/66852242\/hyag025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:39:06Z","timestamp":1780688346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/6\/774\/8472810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag025","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,11]]}}}